BioCryst Pharmaceuticals BCRX Payments to Acquire Debt Securities, Available-for-Sale
Payments to Acquire Debt Securities, Available-for-Sale at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's payments to acquire debt securities, available-for-sale.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's payments to acquire debt securities, available-for-sale?
- BioCryst Pharmaceuticals (BCRX) reported payments to acquire debt securities, available-for-sale of $0 in Q1 2026.
- How has BioCryst Pharmaceuticals's payments to acquire debt securities, available-for-sale changed year-over-year?
- BioCryst Pharmaceuticals's payments to acquire debt securities, available-for-sale decreased by 100.0% year-over-year, from $48.76M to $0.
- What is the long-term trend for BioCryst Pharmaceuticals's payments to acquire debt securities, available-for-sale?
- Over 4 years (2021 to 2025), BioCryst Pharmaceuticals's payments to acquire debt securities, available-for-sale has grown at a 126.2% compound annual growth rate (CAGR), from $10.01M to $262.24M.
- What does payments to acquire debt securities, available-for-sale mean?
- Reflects cash used to purchase debt securities classified as available-for-sale, typically as part of a treasury management strategy to earn interest on excess cash. This indicates how the company manages its liquidity and short-term investment portfolio.